Table 1.
Comparative Data of the Study Groups
| Item | T2DM without NAFLD | T2DM with NAFLD | P value |
|---|---|---|---|
| Age (years) | 40.51±15.04 | 51.53±15.10 | 0.000** |
| Sex (F/M) | 42/50 | 80/128 | 0.691 |
| Duration (years) | 3 (1–9.5) | 8 (2–12) | 0.064 |
| Waist circumference (cm) | 91.27±10.78 | 95.34±10.26 | 0.045* |
| BMI (kg/m2) | 26.20±4.18 | 26.50±3.74 | 0.673 |
| ALT (U/l) | 24 (14–39) | 21 (13–29) | 0.351 |
| AST (U/l) | 20 (15–26) | 18 (14–23) | 0.173 |
| TG (mmol/l) | 3.30±2.65 | 2.21±2.06 | 0.338 |
| Albumin (g/dl) | 42.05±4.50 | 40.45±3.14 | 0.040* |
| Platelets (×109/l) | 225.29±51.12 | 218.96±62.81 | 0.564 |
| Glucose (mg/dl) | 8.12±4.03 | 8.44±4.38 | 0.678 |
| HbA1C (%) | 7.46±1.76 | 8.60±1.87 | 0.015* |
| Insulin (μU/mL) | 8 (4.6–11.6) | 9.4 (5.4–14.5) | 0.260 |
| HOMA-IR | 1.34 (1.14–1.56) | 1.54 (1.0–1.9) | 0.709 |
| Calcium (mg/dl) | 2.25±0.09 | 2.23±0.09 | 0.418 |
| Phosphate (mg/dl) | 1.31±0.20 | 1.27±0.20 | 0.263 |
| Types of hypoglycemic drugs | Insulin, insulin secretagogues, Alpha-glucosidase Inhibitors, Metformin, DPP-IV inhibitor | Insulin, insulin secretagogues, Alpha-glucosidase Inhibitors, Metformin, DPP-IV inhibitor |
Notes: T2DM with NAFLD compared with T2DM without NAFLD; *P<0.05, **P<0.01. Results with statistical significance were marked in bold.
Abbreviations: BMI, body mass index; ALT, alanine transaminase; AST, aspartate aminotransferase; TG, triglyceride; HOMA-IR, homeostasis model assessment of insulin resistance index.